NEW YORK, July 29, 2016 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit
has been commenced in the USDC for the Eastern District of North Carolina on behalf of investors who purchased TransEnterix, Inc.
(NYSE MKT:TRXC) securities between February 10, 2016 and May 10, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/transenterix. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to
disclose that (a) there were deficiencies within the Company’s 510(k) application to the Food and Drug Administration which
undermined the likelihood that the SurgiBot System would receive FDA clearance; (b) that as a result of these deficiencies,
TransEnterix would be unable to commercialize the SurgiBot in 2016; and (c) consequently, the Company’s ability to obtain approval
for and commercialize its other robotic surgery platforms in the U.S. would be impaired.
If you suffered a loss in TransEnterix you have until August 1, 2016 to request that the Court appoint you as
lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional
information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/transenterix.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving
financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar
outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: vw@wongesq.com
